Gilead: New Data Shows Biktarvy As Effective Treatment Regimen In Black Americans With HIV


(RTTNews) – Gilead Sciences, Inc. (GILD) announced Wednesday that new 48-week data from the BRAAVE 2020 study shows Biktarvy as an effective treatment regimen in Black Americans with HIV.
BRAAVE 2020, a Phase 3 clinical trial, is evaluating the safety and efficacy of switching to Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg …..


*This post contains affiliate links*